STOCK TITAN

Corbus Pharmaceuticals (CRBP) grants RSUs and stock options to director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corbus Pharmaceuticals director Winston Kung received new equity awards as part of his compensation. On May 19, 2026, he was granted 3,800 restricted stock units (RSUs), which will settle in common shares and vest 100% one year from the grant date. Following this award, his direct common stock holdings total 14,166 shares, including 8,600 unvested RSUs subject to their existing vesting schedules. On the same date, he also received stock options for 12,300 shares of common stock at an exercise price of $9.15 per share, which will also vest in full on the one-year anniversary of the grant.

Positive

  • None.

Negative

  • None.
Insider Kung Winston
Role null
Type Security Shares Price Value
Grant/Award Stock options (right to buy) 12,300 $0.00 --
Grant/Award Common Stock, par value $0.0001 per share 3,800 $0.00 --
Holdings After Transaction: Stock options (right to buy) — 12,300 shares (Direct, null); Common Stock, par value $0.0001 per share — 14,166 shares (Direct, null)
Footnotes (1)
  1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
RSU grant 3,800 RSUs Granted on May 19, 2026; vest 100% after one year
Options granted 12,300 options Granted on May 19, 2026; underlying common stock
Option exercise price $9.15 per share Exercise price for 12,300 stock options
Shares after transaction 14,166 shares Total direct common stock holdings after RSU grant
Unvested RSUs 8,600 RSUs Previously reported unvested RSUs still subject to vesting schedules
restricted stock units ("RSUs") financial
"On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting schedule financial
"This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
Equity Compensation Plan financial
"The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan."
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.
stock options financial
"Stock options (right to buy)"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kung Winston

(Last)(First)(Middle)
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
500 RIVER RIDGE DRIVE

(Street)
NORWOOD MASSACHUSETTS 02062

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.0001 per share05/19/2026A3,800(1)A$014,166(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock options (right to buy)$9.1505/19/2026A12,300 (3)05/19/2026Common Stock12,300$012,300D
Explanation of Responses:
1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
2. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.
3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
/s/ Meghan Houghton, attorney-in-fact for Winston Kung05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Corbus (CRBP) director Winston Kung receive on May 19, 2026?

On May 19, 2026, Winston Kung received 3,800 restricted stock units and stock options for 12,300 shares at a $9.15 exercise price. Both the RSUs and the options vest 100% on the one-year anniversary of the grant date.

How many Corbus (CRBP) shares does Winston Kung hold after these awards?

After the May 19, 2026 awards, Winston Kung directly holds 14,166 shares of Corbus common stock. This total includes previously reported unvested RSUs, with 8,600 of those RSUs remaining unvested and subject to their respective vesting schedules as disclosed.

When do Winston Kung’s new Corbus (CRBP) RSUs and options vest?

Both the 3,800 restricted stock units and the 12,300 stock options granted to Winston Kung vest 100% on the one-year anniversary of the May 19, 2026 grant date. Vesting must occur before he receives shares or can exercise the options.

Are Winston Kung’s Corbus (CRBP) equity awards open-market purchases or compensation grants?

The Form 4 shows Winston Kung’s transactions as compensation-related grants, not open-market purchases. The RSUs and stock options were awarded under Corbus’s 2024 Equity Compensation Plan, reflecting non-cash equity incentives rather than discretionary buying or selling in the market.

What is the exercise price of Winston Kung’s new Corbus (CRBP) stock options?

The stock options granted to Winston Kung on May 19, 2026 have an exercise price of $9.15 per share. They cover 12,300 underlying common shares and will vest in full one year after the grant date, according to the disclosed terms.